IP Library Granted Patent US 9,402,886
Granted Patent B2
US 9,402,886 · App. 14/480,486 · Granted Aug 2, 2016

Compositions and methods of using chondroitinase ABCI mutants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,402,886
App. No.
14/480,486
Granted
Aug 2, 2016
Kind
B2
Abstract

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Claims (8)

1. A pharmaceutical composition comprising a therapeutically effective amount of mutant chondroitinase ABC I enzyme selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, and a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 1, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 2, and a pharmaceutically acceptable excipient.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 3, and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 4, and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 5, and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 6, and a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of mutant chondroitinase ABC I enzyme SEQ ID NO: 7, and a pharmaceutically acceptable excipient.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: HUNTER, ELIZABETH
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 038998/0798 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2014
From: CAGGIANO, ANTHONY O.; IACI, JENNIFER; VECCHIONE, ANDREA; MARKENSOHN, ELIZABETH
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 033693/0557 →